# Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

> **NCT01101269** · NA · TERMINATED · sponsor: **University of Virginia** · enrollment: 6 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ACEI or ARB
- **DRUG:** Lisinopril

## Key facts

- **NCT ID:** NCT01101269
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Slow Recruitment
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101269, "Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01101269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*